CN101486706A - 一种奥美拉唑钠化合物及其合成方法 - Google Patents
一种奥美拉唑钠化合物及其合成方法 Download PDFInfo
- Publication number
- CN101486706A CN101486706A CNA2009101189363A CN200910118936A CN101486706A CN 101486706 A CN101486706 A CN 101486706A CN A2009101189363 A CNA2009101189363 A CN A2009101189363A CN 200910118936 A CN200910118936 A CN 200910118936A CN 101486706 A CN101486706 A CN 101486706A
- Authority
- CN
- China
- Prior art keywords
- methoxyl group
- omeprazole
- sodium
- benzoglyoxaline
- synthetic method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940063517 omeprazole sodium Drugs 0.000 title claims abstract description 17
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 5
- 230000002194 synthesizing effect Effects 0.000 title description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 38
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims abstract description 37
- 238000010189 synthetic method Methods 0.000 claims abstract description 31
- 238000006243 chemical reaction Methods 0.000 claims abstract description 30
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960000381 omeprazole Drugs 0.000 claims abstract description 25
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000009518 sodium iodide Nutrition 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 4
- 239000003054 catalyst Substances 0.000 claims abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 74
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000012046 mixed solvent Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 159000000000 sodium salts Chemical class 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- LELDJUYQEMKHJH-UHFFFAOYSA-N 4-methoxy-2,3,5-trimethylpyridine Chemical class COC1=C(C)C=NC(C)=C1C LELDJUYQEMKHJH-UHFFFAOYSA-N 0.000 claims description 5
- 230000001143 conditioned effect Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- LCJDHJOUOJSJGS-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridin-1-ium;chloride Chemical compound Cl.COC1=C(C)C=NC(CCl)=C1C LCJDHJOUOJSJGS-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 16
- 239000000047 product Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000001711 oxyntic cell Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- -1 sodium alkoxide Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910118936 CN101486706B (zh) | 2009-03-09 | 2009-03-09 | 一种奥美拉唑钠化合物及其合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910118936 CN101486706B (zh) | 2009-03-09 | 2009-03-09 | 一种奥美拉唑钠化合物及其合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101486706A true CN101486706A (zh) | 2009-07-22 |
CN101486706B CN101486706B (zh) | 2012-12-19 |
Family
ID=40889783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910118936 Expired - Fee Related CN101486706B (zh) | 2009-03-09 | 2009-03-09 | 一种奥美拉唑钠化合物及其合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101486706B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102351845A (zh) * | 2011-08-21 | 2012-02-15 | 苏州二叶制药有限公司 | 一种高对映体选择性制备s-(-)-奥美拉唑的方法 |
CN103204841A (zh) * | 2013-05-09 | 2013-07-17 | 成都天台山制药有限公司 | 奥美拉唑钠及制备方法 |
CN103664887A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 埃索美拉唑钠的制备方法 |
CN103664888A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 埃索美拉唑镁三水合物的制备方法 |
WO2014080422A3 (en) * | 2012-11-26 | 2014-06-19 | Emcure Pharmaceuticals Limited | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof |
CN104045627A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种奥美拉唑纯化方法 |
CN104788426A (zh) * | 2015-04-02 | 2015-07-22 | 天津大学 | 一种奥美拉唑钠半水合物及其制备方法 |
CN104945380A (zh) * | 2015-06-17 | 2015-09-30 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
CN106008464A (zh) * | 2016-05-23 | 2016-10-12 | 江苏中邦制药有限公司 | 5-甲氧基-2-(4-甲氧基-3,5-二甲基-2-吡啶基)甲基硫代-1h-苯并咪唑粗品的精制方法 |
CN107400118A (zh) * | 2017-08-29 | 2017-11-28 | 信泰制药(苏州)有限公司 | 埃索美拉唑中间体的制备方法 |
CN113121499A (zh) * | 2021-04-13 | 2021-07-16 | 海南锦瑞制药有限公司 | 奥美拉唑的合成方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59510667D1 (de) * | 1994-07-20 | 2003-06-05 | Altana Pharma Ag | Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien |
WO2007088559A1 (en) * | 2006-02-01 | 2007-08-09 | Jubilant Organosys Limited | Process for producing substituted sulphoxides |
US7786309B2 (en) * | 2006-06-09 | 2010-08-31 | Apotex Pharmachem Inc. | Process for the preparation of esomeprazole and salts thereof |
-
2009
- 2009-03-09 CN CN 200910118936 patent/CN101486706B/zh not_active Expired - Fee Related
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102351845B (zh) * | 2011-08-21 | 2012-11-14 | 苏州二叶制药有限公司 | 一种高对映体选择性制备s-(-)-奥美拉唑的方法 |
CN102351845A (zh) * | 2011-08-21 | 2012-02-15 | 苏州二叶制药有限公司 | 一种高对映体选择性制备s-(-)-奥美拉唑的方法 |
CN104797572A (zh) * | 2012-11-26 | 2015-07-22 | 安治制药公司 | 作为酸分泌抑制剂的吡啶酮衍生物及其制备方法 |
US9447094B2 (en) | 2012-11-26 | 2016-09-20 | Emcure Pharmaceuticals Limited | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof |
EA028205B1 (ru) * | 2012-11-26 | 2017-10-31 | Эмкьюар Фармасьютикалз Лимитед | Производные пиридона в качестве ингибиторов секреции кислоты и способ их получения |
CN108484643A (zh) * | 2012-11-26 | 2018-09-04 | 安治制药公司 | 作为酸分泌抑制剂的吡啶酮衍生物及其制备方法 |
WO2014080422A3 (en) * | 2012-11-26 | 2014-06-19 | Emcure Pharmaceuticals Limited | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof |
US9522924B1 (en) | 2012-11-26 | 2016-12-20 | Emcure Pharmaceuticals Limited | Pyridone derivatives as acid secretion inhibitors and process for preparation thereof |
CN103204841B (zh) * | 2013-05-09 | 2014-06-25 | 成都天台山制药有限公司 | 奥美拉唑钠及制备方法 |
CN103204841A (zh) * | 2013-05-09 | 2013-07-17 | 成都天台山制药有限公司 | 奥美拉唑钠及制备方法 |
CN103664888B (zh) * | 2013-12-18 | 2015-07-08 | 成都医路康医学技术服务有限公司 | 埃索美拉唑镁三水合物的制备方法 |
CN103664888A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 埃索美拉唑镁三水合物的制备方法 |
CN103664887A (zh) * | 2013-12-18 | 2014-03-26 | 成都医路康医学技术服务有限公司 | 埃索美拉唑钠的制备方法 |
CN104045627A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种奥美拉唑纯化方法 |
CN104788426A (zh) * | 2015-04-02 | 2015-07-22 | 天津大学 | 一种奥美拉唑钠半水合物及其制备方法 |
WO2016155334A1 (zh) * | 2015-04-02 | 2016-10-06 | 天津大学 | 一种奥美拉唑钠半水合物及其制剂和制备方法 |
CN104788426B (zh) * | 2015-04-02 | 2015-12-30 | 天津大学 | 一种奥美拉唑钠半水合物及其制备方法 |
WO2016202212A3 (zh) * | 2015-06-17 | 2017-03-09 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
CN104945380A (zh) * | 2015-06-17 | 2015-09-30 | 海南灵康制药有限公司 | 一种采用粒子过程晶体产品分子组装与形态优化技术制备的奥美拉唑钠化合物及其制剂 |
CN106008464A (zh) * | 2016-05-23 | 2016-10-12 | 江苏中邦制药有限公司 | 5-甲氧基-2-(4-甲氧基-3,5-二甲基-2-吡啶基)甲基硫代-1h-苯并咪唑粗品的精制方法 |
CN107400118A (zh) * | 2017-08-29 | 2017-11-28 | 信泰制药(苏州)有限公司 | 埃索美拉唑中间体的制备方法 |
CN113121499A (zh) * | 2021-04-13 | 2021-07-16 | 海南锦瑞制药有限公司 | 奥美拉唑的合成方法及应用 |
CN113121499B (zh) * | 2021-04-13 | 2022-05-31 | 海南锦瑞制药有限公司 | 奥美拉唑的合成方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101486706B (zh) | 2012-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101486706B (zh) | 一种奥美拉唑钠化合物及其合成方法 | |
CA2726599C (en) | Process for treprostinil salt preparation | |
EP3097096A1 (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1- (arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation | |
ITMI20090361A1 (it) | Procedimento per la preparazione delbonsentan | |
CN109851653B (zh) | 16α-羟基泼尼松龙的制备方法 | |
JP6592085B2 (ja) | レバプラザン塩酸塩の調製方法 | |
CA1216585A (en) | Quinolonecarboxylic acids as antibacterial agents | |
JP2011500555A (ja) | イオン性液体媒質中でのモンテルカスト酸の製造方法 | |
CN102887885B (zh) | 一种埃索美拉唑钠的制备方法 | |
JP2015512381A5 (zh) | ||
CN102863426A (zh) | 改进的Sharpless不对称环氧化反应制备左旋泮托拉唑钠的方法 | |
CN112707889A (zh) | 一种兰索拉唑的合成方法 | |
CN102241671A (zh) | 前体相及其用于制备奥美拉唑对映体的四水合镁盐的用途 | |
CN104781231B (zh) | 制备曲伏前列素的方法 | |
CN114920683A (zh) | 一种Boc-脯氨醛以及(R,E)-(1-甲基吡咯烷-2-基)丙烯酸的制备方法 | |
WO2019213545A1 (en) | Synthesis of cerdulatinib | |
EP2598485B1 (en) | Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same | |
CN101863830B (zh) | 2-氨基-5-溴异烟酸的合成方法 | |
KR20180105450A (ko) | 피마살탄 콜린염 및 이의 수화물의 제조방법 | |
JP2005306874A (ja) | パントプラゾールナトリウム塩の多形体およびその製造方法 | |
CN103087080A (zh) | 一种盐酸头孢卡品酯的制备方法及其合成中间体 | |
CN102731407A (zh) | 一种制备替米沙坦的方法 | |
WO2010018895A1 (en) | Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives | |
CN105753870A (zh) | 一种西地那非杂质f及其制备方法和应用 | |
US8198455B2 (en) | Process for the preparation of dexlansoprazole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: DENG JUJUAN Effective date: 20130729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310016 HANGZHOU, ZHEJIANG PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130729 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd. Address before: 310016 room 1, 1801 Qian Tang garden, Jianggan District Shengshi, Hangzhou, Zhejiang Patentee before: Deng Jujuan |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121219 Termination date: 20160309 |